UY34478A - Comprimido recubierto seco - Google Patents

Comprimido recubierto seco

Info

Publication number
UY34478A
UY34478A UY0001034478A UY34478A UY34478A UY 34478 A UY34478 A UY 34478A UY 0001034478 A UY0001034478 A UY 0001034478A UY 34478 A UY34478 A UY 34478A UY 34478 A UY34478 A UY 34478A
Authority
UY
Uruguay
Prior art keywords
coated tablet
dry coated
dry
tablet
scan
Prior art date
Application number
UY0001034478A
Other languages
English (en)
Inventor
Mizuno Yumiko
Kawano Tetsuya
Mima Yasushi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34478A publication Critical patent/UY34478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un comprimido recubierto seco que muestra una elevada estabilidad del ingrediente activo (inhibidor de bomba protónica, aspirina), que expresa estable y rápidamente el efecto farmacológico del ingrediente activo después de la adminis tración. Un comprimido recubierto seco que tiene un núcleo interno y una capa externa, en donde el núcleo interno es un comprimido recubierto entérico que contiene ácido acetilsalicílico y la capa externa contiene microgránulos entéricos que contienen un inhibidor de bomba protónica.
UY0001034478A 2011-11-30 2012-11-29 Comprimido recubierto seco UY34478A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011262679 2011-11-30

Publications (1)

Publication Number Publication Date
UY34478A true UY34478A (es) 2013-06-28

Family

ID=47428946

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034478A UY34478A (es) 2011-11-30 2012-11-29 Comprimido recubierto seco

Country Status (15)

Country Link
US (2) US9433632B2 (es)
EP (1) EP2785331B1 (es)
JP (1) JP5925318B2 (es)
KR (1) KR101952478B1 (es)
CN (1) CN104080446B (es)
AR (1) AR089032A1 (es)
CA (1) CA2857457C (es)
ES (1) ES2561098T3 (es)
HK (1) HK1197581A1 (es)
MY (1) MY186477A (es)
PH (1) PH12014501218B1 (es)
SG (1) SG11201402400YA (es)
TW (1) TWI630002B (es)
UY (1) UY34478A (es)
WO (1) WO2013081177A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6289367B2 (ja) 2012-06-05 2018-03-07 武田薬品工業株式会社 有核錠
TW201532635A (zh) 2013-05-21 2015-09-01 Takeda Pharmaceutical 口腔內崩解錠
AU2015330937B2 (en) * 2014-10-08 2021-07-15 Theriva Biologics, Inc. Beta-lactamase formulations and uses thereof
TWI710379B (zh) * 2015-07-30 2020-11-21 日商武田藥品工業股份有限公司 錠劑
US20210113475A1 (en) * 2017-04-18 2021-04-22 Sensient Colors Llc Dosage form coating composition and method of making and using the same
US11419824B2 (en) 2017-12-29 2022-08-23 Laxxon Medical Ag Drug delivery system
KR20190092805A (ko) 2018-01-31 2019-08-08 삼진제약주식회사 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물
EP4091605A1 (en) 2021-05-19 2022-11-23 G.L. Pharma GmbH Pharmaceutical tablet comprising acetylsalicylic acid
KR20230149188A (ko) 2022-04-19 2023-10-26 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
WO2023204397A1 (ko) * 2022-04-19 2023-10-26 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
KR20240043707A (ko) 2022-09-27 2024-04-03 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH04346930A (ja) 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
DK1561458T3 (da) 1998-07-28 2010-10-25 Takeda Pharmaceutical Hurtigt henfaldende fast middel
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60124692T2 (de) 2000-04-28 2007-09-13 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten
ES2521690T3 (es) 2000-05-15 2014-11-13 Takeda Pharmaceutical Company Limited Procedimiento para producir un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridil]metil]sulfinil]-bencimidazol
PT1337525E (pt) 2000-12-01 2011-09-01 Takeda Pharmaceutical Processo para a cristalização de (r)- ou (s)-lansoprazole
ATE474559T1 (de) * 2001-06-01 2010-08-15 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CA2554271A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
DE102005047616A1 (de) * 2005-10-05 2007-05-31 Bayer Healthcare Ag Kombination
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
JP5529404B2 (ja) 2008-09-05 2014-06-25 東和薬品株式会社 アスピリン腸溶錠
CA2766524A1 (en) 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
WO2011144994A1 (en) 2010-05-21 2011-11-24 Lupin Limited Pharmaceutical compositions of nsaid and acid inhibitor
MY180677A (en) * 2010-12-03 2020-12-05 Takeda Pharmaceuticals Co Orally disintegrating tablet

Also Published As

Publication number Publication date
PH12014501218A1 (en) 2014-09-08
JP2014533656A (ja) 2014-12-15
SG11201402400YA (en) 2014-06-27
MY186477A (en) 2021-07-22
WO2013081177A1 (en) 2013-06-06
US10238605B2 (en) 2019-03-26
CN104080446A (zh) 2014-10-01
PH12014501218B1 (en) 2014-09-08
CA2857457A1 (en) 2013-06-06
ES2561098T3 (es) 2016-02-24
KR101952478B1 (ko) 2019-02-26
AR089032A1 (es) 2014-07-23
EP2785331B1 (en) 2015-11-18
KR20140096157A (ko) 2014-08-04
US20170014347A1 (en) 2017-01-19
US9433632B2 (en) 2016-09-06
US20140335181A1 (en) 2014-11-13
EP2785331A1 (en) 2014-10-08
TWI630002B (zh) 2018-07-21
CA2857457C (en) 2018-05-01
TW201328726A (zh) 2013-07-16
JP5925318B2 (ja) 2016-05-25
CN104080446B (zh) 2018-06-29
HK1197581A1 (zh) 2015-01-30

Similar Documents

Publication Publication Date Title
UY34478A (es) Comprimido recubierto seco
UY34134A (es) Contenedor aislado
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UY34206A (es) Anticuerpo monoclonal de interleucina-31
BR112014009526A2 (pt) imunoterapia com base em pd-l1
UY34365A (es) Compuestos heterociclicos
BR112014015292A2 (pt) processamento de biomassa
DK3053932T3 (da) Hidtil ukendte ctla4-ig-immunoadhesiner
BR112014015290A8 (pt) processamento de biomassa
CO7091177A2 (es) Inhibidores de la beta-secretasa
BR112014003027A2 (pt) formulação herbicida melhorada
DK2692448T3 (da) Brusehoved
BR112015003294A2 (pt) caldeira de armazenamento
UY4153Q (es) Batería
DK2772001T3 (da) Dynamisk krypteringsfremgangsmåde
CL2011002403S1 (es) Luminaria solar.
UY35015A (es) Máquina eólica
BR112014027219A2 (pt) método
UY34483A (es) Polipeptido
CO7111295A2 (es) Anticuerpo anti-rob04
UY4152Q (es) Batería
BR112015004136A2 (pt) partícula detergente revestida
UY34613A (es) Composición de limpieza
DK2549300T3 (da) Seismisk rystemaskine
UY34375A (es) Pinturas Insecticidas Mejoradas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020